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The zinc transporter Zip14 
(SLC39a14) affects Beta-cell 
Function: proteomics, Gene 
expression, and Insulin secretion 
studies in INS-1E cells
trine Maxel1, Kamille smidt2, Charlotte C. petersen1, Bent Honoré1, Anne K. Christensen1, 
Per B. Jeppesen2,3, Birgitte Brock4, Jørgen Rungby5, Johan Palmfeldt2,6 & Agnete Larsen1
Insulin secretion from pancreatic beta-cells is dependent on zinc ions as essential components of 
insulin crystals, zinc transporters are thus involved in the insulin secretory process. Zip14 (SLC39a14) 
is a zinc importing protein that has an important role in glucose homeostasis. Zip14 knockout mice 
display hyperinsulinemia and impaired insulin secretion in high glucose conditions. Endocrine roles 
for Zip14 have been established in adipocytes and hepatocytes, but not yet confirmed in beta-
cells. In this study, we investigated the role of Zip14 in the INS-1E beta-cell line. Zip14 mRNA was 
upregulated during high glucose stimulation and Zip14 silencing led to increased intracellular insulin 
content. Large-scale proteomics showed that Zip14 silencing down-regulated ribosomal mitochondrial 
proteins, many metal-binding proteins, and others involved in oxidative phosphorylation and insulin 
secretion. Furthermore, proliferation marker Mki67 was down-regulated in Zip14 siRNA-treated cells. 
In conclusion, Zip14 gene expression is glucose sensitive and silencing of Zip14 directly affects insulin 
processing in INS-1E beta-cells. A link between Zip14 and ribosomal mitochondrial proteins suggests 
altered mitochondrial RNA translation, which could disturb mitochondrial function and thereby 
insulin secretion. This highlights a role for Zip14 in beta-cell functioning and suggests Zip14 as a future 
pharmacological target in the treatment of beta-cell dysfunction.
Pancreatic beta-cell dysfunction is a key feature of type 2 diabetes (T2D)1. Zinc is essential for insulin storage2, 
and several zinc transporters of the SLC30A family, which orchestrate the intracellular distribution of free zinc, 
have been associated with T2D pathology3–9. Genome-wide association studies link a common polymorphism 
within the zinc transporter ZNT8, exporting zinc to insulin granules6,7, with an increased risk of T2D8. Similarly, 
ZNT5 is highly present at insulin secretory granules9, and Znt3 and Znt7 play a functional role in insulin secre-
tion3–5. Moreover, the reduced levels of circulating zinc found in individuals with T2D indicate a systemic zinc 
dyshomeostasis in T2D10,11.
Intracellular free zinc is found in picomolar concentrations12,13, but it is ubiquitously involved in cell prolif-
eration, apoptotic pathways, and insulin signaling, e.g. through regulation of tyrosine phosphatase activity14–17. 
Within the normal physiological range, free zinc is protective against oxidative stress12, whereas adverse effects 
of zinc are observed when it accumulates in mitochondria, leading to mitochondrial dysfunction and increased 
production of reactive oxygen species18,19. Mitochondrial function is critical for normal insulin secretion: mito-
chondrially generated ATP causes the closure of ATP-dependent potassium channels, leading to depolarization 
of the cell membrane, Ca2+ influx, and release of insulin by exocytosis20.
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To maintain intracellular zinc homeostasis, the concentration and distribution of zinc are tightly regulated by 
zinc transporters of the SLC30A (ZNTs) and Zrt and Irt-Like Protein (ZIP) family, and by metal-binding metal-
lothioneins (MTs)21. Recent studies indicate an important role for ZIP transporters in the function of beta-cells. 
The ZIP transporters Zip4, Zip6, and Zip7 stimulate insulin secretion and ZIP6 has an anti-apoptotic function in 
GLP treatment22,23.
Recently, ZIP14 has emerged as a transport protein with a general impact on glucose metabolism, growth, and 
adipose tissue functioning24–27. ZIP14 is located mainly at the plasma membrane, where it functions as a Zn2+ 
importing protein, but it has also been implicated in the transport of Fe2+ into liver and pancreas in conditions 
involving iron overload28–30. The Zip14 knockout mouse is characterized by hyperinsulinemia, however, with 
signs of impaired insulin secretion upon high glucose stimulation, as well as impaired hepatic gluconeogenesis 
and glycolysis26,31. An increased insulin content is observed in beta-cells of Zip14 knockout animals26, along-
side decreased proliferative and differentiation potential of several cell types24,25,27,32. ZIP14 is highly expressed 
in human liver and pancreas33, and it is present in both the alpha- and beta-cells of the human pancreas when 
investigated by immunofluorescence34. In human type 2 diabetic individuals, signs of a low pancreatic Zip14 
expression levels are observed22.
In this study, the INS-1E model of insulin-producing beta-cells was used. INS-1E cells originate from rat insu-
linoma cells and are characterized by a stable glucose-induced insulin secretion with a dose-related response sim-
ilar to isolated rat islets35,36. The aim of this study was to confirm the presence of Zip14 at the protein level in the 
INS-1E cells and to characterize its regulation and the role of Zip14 in the beta-cell, with regard to the regulation 
of insulin processing, cell survival, and, using a large-scale proteomic approach, the regulation of other proteins.
Materials and Methods
Cultivation of INS-1E cells. INS-1E cells, provided by Prof. Wollheim and Prof. Maechler, Switzerland, 
were cultivated as originally described35,36, in a 5% CO2-containing atmosphere in RPMI 1640 medium (Lonza, 
Verviers, Belgium) containing 11 mM glucose, 2 mM glutamine, 10% heat-inactivated fetal bovine serum, 100 U/
ml penicillin, 100 g/ml streptomycin, and 50 μM beta-mercaptoethanol. Cell passage numbers below 100 were 
used, and the capacity for glucose-induced insulin secretion was confirmed prior to experiments.
Zip14, Znt8, and Insulin (Ins) mRNA expression measurement using PrimeFlow. PrimeFlow 
experiments were undertaken using PrimeFlow RNA Assays (eBioscience, San Diego, CA, USA), based on 
Fluorescent in situ hybridization (FISH) principle.
INS-IE cells were cultivated in RPMI 1640 medium (11 mM glucose) for 3 d and subsequently stimulated with 
5, 11, 16 or 24 mM glucose for 24 h (4–6 replicates). The PrimeFlow procedures were performed according to the 
manufacturer’s protocol using 1–2 million cells stained with viability dye (1 µl/ml; Fixable Viability Dye eFluor 
450, eBioscience).
Samples were analyzed using a LSR Fortessa (BD Biosciences, San Jose, CA, USA) equipped with 405, 488, 
561, and 640 nm lasers. As control samples, unstained cells cultured in 5, 11, 16, and 24 mM glucose were used for 
autofluorescence measurements as well as positive control beta-actin probed cells (part of the PrimeFlow RNA 
Assay), conjugated with AlexaFluor 488, AlexaFluor 647, and AlexaFluor 750. Fluorescence minus one (FMO) 
controls and single color samples of Insulin, Zip14, Zip8, and the fixable viability dye eFluor 450, were included 
for flow cytometry gating and fluorescence compensation. For gating strategy please refer to Supplementary 
Material 1.
For each sample, 300,000 cells were collected and data were analyzed using FlowJo software (v. 10.0.8, FlowJo 
LLC, Ashland, OR, USA). Data were given as the median fluorescent value for the 300,000 cells collected for each 
sample. Data are presented as the mean median fluorescence value ± SEM, and groups were compared using the 
Kruskal-Wallis test, followed by Dunn’s post-test where appropriate (GraphPad Prism 5, San Diego, CA, USA; 
level of significance, p < 0.05).
Transfection procedure. Cells (100,000) were seeded into 24-well plates and grown in supplemented 
RPMI 1640 medium (11 mM glucose), as described, but without any antibiotics. Transfection procedure 
were performed as previously described5, using siRNA targeting Zip14 (ON-TARGET plus Rat Slc39a14 
siRNA SMARTpool, Thermo Fischer Scientific) and, as a control, non-targeting siRNA (ON-TARGET plus 
Non-targeting siRNA, Thermo Fischer Scientific). The target sequences of the ZIP14 siRNA were as follows: 
GUAUAUUGCUCUAGCCGAU, GCUCAAAGGGGUUCGAUAU, CCACAACUUCAGUGAGCGA, and 
GAGCUGGGAGACUUCGUUA. The transfection efficiency was assessed by measurement of mRNA expression 
levels in all experiments and investigated once at the protein level using targeted proteomic analysis, as described 
below.
RNA extraction and real-time PCR. RNA was extracted using Qiagen RNAeasy Mini kits (VWR) and 
evaluated spectrophotometrically and by agarose gel electrophoresis. RNA was reverse transcribed into cDNA 
using the ImProm-IITM Reverse Transcription System (Promega, Madison, Wisconsin, USA) and oligo (dT)15 
primers. cDNA was checked for genomic DNA contamination by PCR analysis using the Qiagen HotStarTaq 
Master Mix Kit (VWR) and an intron-spanning primer-set for beta-actin (TAC, Copenhagen, Denmark). 
Quantitative real-time PCR was performed in duplicate with IQ SYBR Green Supermix (Roche applied Science, 
Germany) in a MyiQ Single-Color Real-time PCR detection system (Bio-Rad, Denmark). Results were analyzed 
with iQ Optical System Software, V. 2.0. Starting quantities were calculated using a standard curve. Values were 
normalized to the geometric mean of up to three house-keeping genes (Beta-actin, Cyclophilin A, and HSP90ab1). 
The geNorm method (geNorm 3.5) was used to confirm the stability of the house-keeping genes37.
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Transfection efficiency was checked by real-time PCR in all experiments by comparing gene expression of 
Zip14 in Zip14 siRNA-treated cells vs. control siRNA-treated cells (n = 6 per group). Gene expression of insulin 
(Ins), Bax, Bcl-2, metallothionein-1A (Mt1a), metallothionein-3 (Mt3), Znt1, Znt3, Znt5, Znt8, Zip6, Zip9, and 
Zip13 was measured after transfection of INS-1E cells, comparing Zip14 siRNA- and control siRNA-treated cells 
(n = 6 per group). The primers used and gene ID numbers are listed in Supplementary Material 2.
Data are presented ± SEM and were compared using the Mann-Whitney U-test (GraphPad Prism 5; level of 
significance, p < 0.05).
Targeted and large scale proteomic studies. Transfected INS-1E cells (Zip14 siRNA and control 
siRNA) were harvested and lysed. Protein concentrations were measured using Pierce BCA Protein Assay 
Reagent kits (Bie & Berntsen A/S, Denmark). See Supplementary Material 3 for details on proteomics methods.
In targeted analysis, using selected reaction monitoring mass spectrometry (MS), the protein level of Zip14 
was measured by specific targeting of a unique Zip14 peptide (SEFQEFCPTILQQLDSR) sequence using an iso-
topically labeled peptide standard of the same sequence (JPT Technology, Berlin, Germany). Five replicate sam-
ples of Zip14 siRNA- and control siRNA transfected cells were analyzed as previously described38. Briefly, proteins 
were separated by SDS-PAGE, in-gel trypsin digested and resulting peptides were C18 purified and analyzed by 
nano-liquid chromatography (LC)-MS/MS consisting of an Ultimate 3000 LC (Thermo Fisher Scientific) coupled 
to a TSQ Vantage triple quadrupole mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA). Raw data 
files from the LC-MS/MS analysis were imported into Skyline software39 and the ratios between the endogenous 
(light) and internal standard (heavy) peptides were calculated. All samples were analyzed twice by Triple Q MS. 
The mean ratio (endogenous Zip14 specific peptide/heavy labeled standard peptide) for each group was calcu-
lated using Excel, and the groups were compared using the Mann-Whitney U-test (Microsoft Excel and GraphPad 
Prism 5; level of significance, p < 0.05).
By the use of large scale proteomics the regulation of cellular proteins was evaluated following Zip14 silenc-
ing. An isobaric tag was added to 70 µg of protein from Zip14 siRNA- and control siRNA-treated cells (n = 4 
replicates) using a tandem mass tag (TMT) 10plex Mass Tag Labeling Kit (Applied Biosystems, Foster City, CA, 
USA), according to the manufacturer’s protocol. Samples were subsequently purified by strong cation exchange, 
fractionated by isoelectric focusing, and peptides were extracted and C18 purified, all as previously described40. 
Samples were analyzed twice by the use of a nano-LC (Ultimate 3000, Dionex) coupled to a mass spectrometer 
(Orbitrap Fusion, Thermo Fisher Scientific, Bremen, Germany) through an EASY-Spray nano-electrospray ion 
source (Thermo Scientific). Data files were merged and analyzed using Mascot v. 2.5.1 (Matrix Science, London, 
UK) in Proteome Discoverer 2.1 (Thermo Scientific). The MS data were searched against the SwissProt Rattus 
database downloaded in May 2016. Normalization to the summed intensities of the tandem mass tag signal was 
applied to compensate for possible variation in the starting material. The false discovery rate (FDR) criterion for 
peptides was q < 0.01. Only proteins with an identification score ≥ 30 (corresponding to a protein identification 
significance of 0.001) were considered, as well as proteins with at least three quantitative scans and one protein 
unique peptide, yielding 3431 proteins. Mean protein ratios were calculated for each protein as the mean abun-
dance in the four Zip14 siRNA-treated samples divided by the mean abundance in control siRNA-treated samples. 
A significant fold change was defined as 2× global standard error of the 3431 proteins (2 × 0.068 = 0.136). FDR 
was calculated from p-values (estimated by Student’s t-test) using the Benjamini and Hochberg’s method41. A 
FDR < 0.05 was used. Fifty-two proteins met the fold-change and FDR criteria. For gene ontology analysis, to 
obtain protein groups, wider criteria, defined as a p value < 0.05 and a significant fold change, were applied, 
yielding 121 proteins. For ontology analysis, the Functional Annotation tool from the Database for Annotation 
Visualization and Integrated Discovery (DAVID) was used (DAVID 6.8 Beta; https://david-d.ncifcrf.gov/). 
The total list of the 3431 proteins found within the samples was selected as background. An enrichment score 
(ES) ≥ 1.3, equal to 0.05 on a non-log scale, was set as the level of significance42. Three protein lists were analyzed 
for functional enrichment; one included both up- and downregulated proteins and two consisted of only either 
down- or upregulated proteins. Mitocarta 2.0 compendium was used to identify mitochondrial proteins within 
our dataset of the 3431 quantified proteins43, and data from KEGG pathway database was applied to filter out 
proteins of the central metabolic pathways44.
Further details and technical descriptions on proteomic analyses are found in Supplementary Material 3. One 
sample was excluded in both targeted and large scale analysis due to an outlying calculated Zip14 level (Zip14 
siRNA treated sample).
Western blot of chromogranin a (chga). The same samples of transfected INS-1E cells (Zip14 siRNA and 
control siRNA) were used as in the proteomic experiments.
Protein samples were dissolved in sample buffer (Laemmli buffer, Biorad, Copenhagen, Denmark) and DTT 
(dithiothreitol) and treated for 5 minutes at 95 °C. 5 μg of protein were used. Protein samples were separated on a 
4–12% CRIT XT BIS-TRIS GEL (Biorad) and transferred to a PVDF membrane (Biorad). The membranes were 
blocked with 5% fat-free milk in tris-buffered saline containing 0.1% Tween-20 for 1.5 h. Primary antibody were 
added and membranes were incubated overnight at 4 °C, where after a horseradish peroxidase (HRP)-conjugated 
secondary antibody were added and incubated for 2 h at room temperature. Visualization were performed using 
Clarity ECL or Clarity ECL max (Biorad).
Primary Antibodies: Chromogranin A mouse monoclonal antibody, dilution 1:6000 (Proteintech), b-actin 
mouse monoclonal antibody, dilution 1:300000 (Sigma Aldrich, St Louis, Missouri, USA). Secondary antibody: 
donkey anti-mouse IgG-HRP, dilution 1:6000 (Santa Cruz Biotechnology, Dallas, Texas, USA). Due to lack of 
sample material 9 samples were included for western blot. B-actin was used as internal control. The intensities 
of Chga were normalized to the corresponding intensity of the internal control (b-actin) in each lane to obtain a 
normalized quantification.
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The Mann-Whitney U-test was used to compare Zip14 siRNA-treated cells with control cells (GraphPad Prism 5; 
level of significance, p < 0.05).
Intracellular and secreted insulin measurements. To evaluate the ability of the transfected cells to 
respond to glucose stimuli as well as to quantify the insulin secretion capacity, the cells were exposed to differ-
ent glucose concentrations, ranging from low to high glucose compared to the basic condition of 11 mM glu-
cose. Cells were glucose stimulated in a period of 24 h. Transfected cells (Zip14 siRNA and control siRNA) were 
stimulated with RPMI 1640 medium containing either 5 mM (lower than average glucose/slightly hypoglycemic 
condition), 16 mM (slightly elevated glucose), or 24 mM (high glucose exposure) glucose (n = 6 replicates). Prior 
to insulin and protein measurements, growth media was replaced by Krebs-Ringer bicarbonate HEPES buffer 
containing the same glucose concentrations for 2 h, after which media, destined for secreted insulin measure-
ment, were collected, and cells were harvested for protein and intracellular insulin measurements, as previously 
described in detail5. Protein measurements were performed using the BCA Protein Assay Reagent Kit. One sam-
ple was excluded due to a significant outlying protein concentration (control siRNA sample at 16 mM). Secreted 
and intracellular insulin measurements were performed using Rat Insulin Elisa kits from DRG Diagnostics 
(VWR, Denmark), following the manufacturer’s instructions. For each sample, secreted and intracellular insulin 
measurements were normalized to the protein content.
Mean intracellular and secreted insulin values are presented as (µIU/µg of protein) ± SEM as well as the mean 
ratio of secreted insulin/intracellular insulin ± SEM. Groups were compared using the Mann-Whitney U-test 
(GraphPad Prism 5; level of significance, p < 0.05).
Measurement of viability. Measurement of viability was performed twice on transfected INS-1E cells 
(Zip14 siRNA/control siRNA) stimulated for 24 h with 5, 11, 16, or 24 mM glucose (n = 9). Dead cells were col-
lected from the growth media. Attached cells were washed and trypsinized. The fractions containing dead and 
attached cells were combined. Viability was measured with Via1-cassettes (Chemometec, Denmark) using the 
Nucleocounter NC-3000 platform. Data are presented as mean percentage of viable cells ± SEM, and groups were 
compared using the Mann-Whitney U-test (GraphPad Prism 5; level of significance, p < 0.05).
Apoptosis and necrosis assay. Transfected cells (Zip14 siRNA/control siRNA) were stimulated for 24 h 
in RPMI 1640 medium containing 5, 11, 16, or 24 mM glucose (n = 6 for each group, except n = 4 for the 16 mM 
Control siRNA group). Apoptosis was identified by the measurement of intracellular histone-associated DNA 
fragments and necrosis by the measurement of extracellular histone-associated DNA fragments using a pho-
tometric enzyme immunoassay (Cell Death Detection ELISAPLUS, Roche Applied Science, Germany) follow-
ing the manufacturer’s instructions5. The immunoassay included both a negative as well as a positive control. 
Data are presented as mean optical density (OD) ± SEM. The Mann-Whitney U-test was used to compare Zip14 
siRNA-treated cells with control cells (GraphPad Prism 5; level of significance, p < 0.05).
Results
Effect of high glucose concentrations on Zip14 mRNA expression. Using PrimeFlow-based flow 
cytometry, we measured the effect of glucose concentration on Zip14, Znt8, and insulin (Ins) mRNA expression, 
to determine whether Zip14 is regulated by glucose and whether its expression is co-regulated with insulin mRNA 
levels. Znt8 was used as a positive control for glucose dependence, as we have previously found decreased expres-
sion levels upon high glucose stimulation3,45.
A homogenous response of the cell population was observed in response to glucose stimulation, with a sig-
nificant increase in Zip14 mRNA (p = 0.0123). Statistically significant increases in the Zip14 mRNA signal were 
detected at 16 mM and 24 mM glucose vs. 5 mM (Fig. 1A). Znt8 mRNA was also significantly regulated by glucose 
(p = 0.0071), with a homogenous response among the cells. Statistically significant decreases were detected at 
11 mM and 16 mM glucose vs. 5 mM (Fig. 1B). There was no significant effect of glucose concentration on insulin 
(Ins) mRNA (p = 0.3177) (Fig. 1C).
In summary, there was an increase in Zip14 mRNA upon stimulation with high glucose concentrations, while 
Znt8 mRNA was decreased and insulin (Ins) mRNA was statistically unchanged. It should be noted, that a very 
high fluorescent signal was found for insulin (Ins) mRNA potentially masking small changes.
Verification of Zip14 at RNA and protein levels in INS-1E cells. To investigate the effect of Zip14 
within the beta-cell, Zip14 expression was silenced in INS-1E cells using Zip14 siRNA. To verify the presence of 
Zip14 at both the mRNA and protein levels in INS-1E cells, as well as to evaluate the effects of siRNA treatment on 
Zip14 levels, Zip14 expression was measured in Zip14 siRNA- and control siRNA-transfected cells using real-time 
PCR and targeted proteomics.
A significant decrease in Zip14 mRNA expression was observed in Zip14 siRNA-treated cells. Zip14 mRNA 
was reduced by 45–65% in six independent experiments (by 45% in the example shown in Fig. 2A, p = 0.0152).
The protein level of Zip14 was analyzed by selected reaction monitoring MS. Zip14 protein expression was 
reduced by 32% (p = 0.0317) in Zip14 siRNA- vs. control siRNA-transfected cells (Fig. 2B) (by 31% in a second 
analysis, p = 0.0635).
In summary, we confirmed the presence of Zip14 in the INS-1E beta-cell line at both the mRNA and protein 
levels, and demonstrated a siRNA transfection efficiency of 45–65% at the mRNA level resulting in approximately 
30% down-regulation at the protein level.
Effect of Zip14 silencing on the expression of selected zinc transporters and metallothioneins. 
The co-regulation of other zinc transporters that have previously been implicated in beta-cell function, and 
the zinc-sensing metallothioneins, Mt1a and Mt3 was investigated, to determine their regulation and whether 
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Figure 1. Measurements of Zip14, Znt8, and insulin mRNA by PrimeFlow RNA Assay. INS-1E cells were 
incubated with 5, 11, 16, or 24 mM glucose for 24 h. Zip14, Znt8, and insulin (Ins) mRNA levels were measured 
by flow cytometry using specific RNA probes incorporated in PrimeFlow RNA assays. (A) Zip14 mRNA probe, 
(B) Znt8 mRNA probe, and (C) Insulin mRNA probe. (A–C) Mean median fluorescence value ± SEM of 
indicated mRNA probe at 5, 11, 16, and 24 mM glucose. n = 4–6 in each group. *p < 0.05, **p < 0.01 compared 
with 5 mM glucose as reference.
Figure 2. Transfection efficiency. Transfection efficiency was assessed by measurement of mRNA expression 
level by real-time PCR and at the protein level by selected reaction monitoring mass spectrometry. Zip14 
siRNA-treated cells were compared with non-targeting siRNA-treated cells (Control siRNA). (A) Zip14 
mRNA expression (n = 6). Results are expressed as the mean starting quantity of (Zip14/three house-keeping 
genes) ± SEM. (B) ZIP14 protein expressed as a mean ratio of an endogenous ZIP14-specific peptide/a heavy 
labeled standard peptide with the same sequence ± SEM. (Endogen Zip14/Internal standard) (n = 4–5). 
*p < 0.05.
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expression of other zinc transporters might compensate for the down-regulation of Zip14. Znt1 was chosen as the 
widely expressed and main zinc efflux transporter at the plasma membrane, in order to illuminate if a change in 
Zip14-mediated zinc influx would affect the efflux46. Znt8, Znt3 and Znt5 are all localized at the insulin granules 
and in particular Znt8 and Znt3 have been shown to significantly regulate the glucose-stimulated insulin secre-
tion5,47–49. Of the Zip family, Zip6 and Zip9 were investigated as hormone-sensitive transporters that, like Zip14, 
play a role in cell proliferation and apoptosis, while Zip13 was chosen as Zip13- and Zip14 KO-mice display many 
similarities in terms of growth retardation and impaired glucose metabolism50–52.
None of the zinc transporters investigated (Znt1, Znt3, Znt5, Znt8, Zip6, Zip9, and Zip13) showed any 
mRNA response to Zip14 silencing (p = 0.4848, p = 0.69961, p = 0.9372, p = 0.8182, p = 0.9372, p = 0.8182, and 
p = 0.6991, respectively) (Fig. 3). A significant increase in Mt1a expression was observed after Zip14 silencing 
(p = 0.0152), but no difference was detected in Mt3 mRNA expression (p = 0.2403) (Fig. 4A,B).
In summary, no transcriptional compensation was observed by the other zinc transporters investigated, 
including Znt1, Znt3, and Znt8, in response to Zip14 silencing. However, increased expression of the metal-
lothionein Mt1a mRNA was observed.
Figure 3. mRNA expression levels of zinc transporters. Measurements of zinc transporter mRNAs by real-time 
PCR in Zip14 siRNA- and non-targeting siRNA-treated samples (Control siRNA). Results are expressed as the 
mean starting quantity of (gene of interest/three house-keeping genes) ± SEM. (A) ZnT transporters; Znt1, Znt3, 
Znt5, and Znt8. (B) Zip transporters; Zip6, Zip9, and Zip13.
Figure 4. mRNA expression levels of metallothioneins. Measurements of metallothionein mRNA expression by 
real-time PCR in Zip14 siRNA- and non-targeting siRNA-treated (Control siRNA) cells. Results are expressed as 
the mean starting quantity of (gene of interest/three house-keeping genes) ± SEM. (A) Mt1A mRNA expression. 
(B) Mt3 mRNA expression. *p < 0.05.
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Effect of Zip14 silencing on expression of other cellular proteins. We next investigated whether the 
expression of other proteins was regulated by Zip14 silencing using a large-scale proteomic approach.
In total, 3431 proteins were identified (a full list of these can be found in Supplementary Material 4). Of 
these, 52 were found to be differentially regulated (FDR < 0.05) in Zip14 siRNA- vs. control siRNA-treated cells 
(listed in Tables 1–3). From their described properties (Uniprot.org), 11 proteins were identified as metal-binding 
(downregulated: Pdp2, Ranbp2, Resp2, Ampd2, Zfp512, Aco1; upregulated: Edem3, Chga, Srrm2, Adpgk, and 
Rnf213), two with a regulatory effect on insulin secretion (down-regulated, 6-phosphofructo-2-kinase/fructose-2, 
6-biphosphatase 2 (Pfkfb2); and up-regulated, Chromogranin A (Chga)), as well as a down-regulation of the pro-
liferation marker protein (Mki67) was found.
In summary, 52 proteins were found to be differentially regulated after Zip14 silencing, of which 11 were 
identified to be metal-binding, while others have known functions in insulin secretion and cellular proliferation.




Table 1. List of proteins that were regulated by Zip14 silencing. Numbers of proteins that were differentially 
expressed in Zip14 siRNA- and non-targeting siRNA-treated (Control siRNA) cells. Proteins with a fold change 
>1.136 or <0.88, and a false discovery rate <0.05, were included. 52 proteins were found in total, of which 28 
were down-regulated and 24 were up-regulated.
Down-regulated proteins
Gene 
name Accession Number Protein description
Ratio (siRNAZIP14 vs. 
Control siRNA)
Dcp1a D4AE80 mRNA-decapping enzyme 1A 0.70
Pdcd11 D3ZNI3 Protein RRP5 homolog 0.72
Pdp2 A0A0G2JSL7 [Pyruvate dehydrogenase [acetyl-transferring]]-phosphatase 2, mitochondrial 0.76
Cfdp1 A0A0G2K6H5 Craniofacial development protein 1 0.77
Mrps5 D3ZYT2 Mitochondrial ribosomal protein S5 0.78
Reps2 A0A0G2K1L4 RalBP1-associated Eps domain-containing protein 2 0.78
Zfp512 D3ZIF0 Zinc finger protein 512 0.79
Ap2a1 D3ZUY8 Adaptor protein complex AP-2, alpha 1 subunit 0.80
Mki67 D4A0Y6 Protein Mki67 0.80
Nup205 D4A7R3 Nucleoporin 205 kDa 0.81
Ranbp2 M0R3M4 E3 SUMO-protein ligase RanBP2 0.81
Pbdc1 G3V6C3 Protein Pbdc1 0.82
Noc2l E9PTF3 Nucleolar complex protein 2 homolog 0.82
Nop56 Q4KLK7 Nucleolar protein 5 A 0.84
Wdr37 D3ZQ02 WD repeat-containing protein 37 0.84
Sept3 F1LMH0 Neuronal-specific septin-3 0.84
Ampd2 A0A0G2K3U1 AMP deaminase 2 0.85
Tmed4 B5DEM3 Transmembrane emp24 domain-containing protein 4 0.85
Numa1 F7FF45 Nuclear mitotic apparatus protein 1 0.85
Aco1 G3V6S2 Cytoplasmic aconitate hydratase 0.85
Slirp D4A4W6 SRA stem-loop-interacting RNA-binding protein, mitochondrial 0.86
Pacs1 F1LPG3 Phosphofurin acidic cluster sorting protein 1 0.86
Strbp D3ZDD7 Spermatid perinuclear RNA binding protein, isoform 0.87
Hnrnpr Q566E4 Heterogeneous nuclear ribonucleoprotein R 0.87
Osbpl7 A0A0G2K0D5 Oxysterol-binding protein 0.87
Gga3 A0A0G2JV04 Protein Gga3 0.87
Pfkfb2 R9PXY6 6-phosphofructo-2-kinase/fructose-2, 6-biphosphatase 2, isoform CRA_a 0.87
Nop58 Q5PPK6 Nucleolar protein 58 0.88
Table 2. List of down-regulated proteins. List of the 28 proteins that were down-regulated in Zip14 siRNA- vs. 
non-targeting siRNA-treated (Control siRNA) cells. Proteins with a fold change >1.136 or <0.88, and a false 
discovery rate <0.05, were included. Gene name, accession number, and ratio are listed, together with a short 
description (from uni-prot.org, using the descriptions from the human database, when not available for Rattus 
norvegicus).
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As Chga (Chromogranin A) is a key regulatory pro-hormone, substantially affecting insulin secretion53–55 
we chose to validate this protein by western blotting, using the same samples as in the proteomic experiments, 
comparing Zip14 siRNA- and control siRNA-transfected cells. Western blotting confirmed the changes observed 
in Chga levels (Proteomics; ratio 1.18; p = 0.0007. Western blotting; ratio 1.76; p = 0.0635) (Fig. 5, as well as the 
full western blot is available in Supplementary Material 5).
Ontological analysis of the large-scale proteomics data. Functional ontology analysis was used to 
characterize the list of differentially regulated proteins identified by large-scale proteomics following Zip14 silenc-
ing, to determine whether specific functional protein groups were selectively regulated.
121 proteins were included in the gene ontology analysis, which was undertaken using the bioinformatics 
software DAVID 6.8 Beta. Two annotation clusters were identified with an ES ≥ 1.3 (Table 4). When analyzing 
the complete list and the separate list of down-regulated proteins, an annotation cluster containing 11 ribosomal 
Up-regulated proteins
Gene name Accession Protein description
Ratio (siRNAZIP14 
vs. Control siRNA)
Itln1 Q499T8 Intelectin 1 (Galactofuranose binding) 1.15
Rpl22l1 B2RZD5 60S ribosomal protein L22-like 1 1.15
Dera F1M1H0 Deoxyribose-phosphate aldolase 1.16
Gba B2RYC9 Glucosylceramidase 1.16
LOC681282 D3ZDG0 Unknown 1.16
Vgf F1LP80 Neurosecretory protein VGF 1.16
Rnf213 F1M0R1 E3 ubiquitin-protein ligase RNF213 1.17
Rab3b Q6P9W6 Ras-related protein Rab-3B 1.18
Adpgk G3V784 ADP-dependent glucokinase, isoform CRA_a 1.18
Srrm2 A0A0G2K2M9 Serine/arginine repetitive matrix protein 2 1.18
Evi5 D3ZJN9 Ecotropic viral integration site 5 protein 1.18
Chga F8QYX0 Chromogranin A 1.18
Rfc2 Q9QXI2 Replication factor C subunit 2 (Fragment) 1.18
Tspan6 B0BN20 Tetraspanin 1.19
Camk2b F1LNI8 Calcium/calmodulin-dependent protein kinase type II subunit beta 1.20
Tgfbi D4A8G5 Transforming growth factor-beta-induced protein ig-h3 1.22
Cdk12 A0A0G2K5U7 Cyclin-dependent kinase 12 1.23
RGD1560212* A0JPQ5 N-alpha acetyltransferase 11 (88.6% homologue) 1.23
Edem3 D4AB70 alpha-1,2-Mannosidase 1.24
Wnk3 A0A0G2K2Y2 Serine/threonine-protein kinase WNK3 1.25
Cnn2 D3ZRX9 Calponin 1.26
Resp18 A0A0G2JZD6 Regulated endocrine-specific protein 18 1.37
Reep1 D4A193 Receptor expression-enhancing protein 1.39
Muc13 F1M9I3 Mucin-13 2.45
Table 3. List of up-regulated proteins. List of the 24 proteins that were up-regulated in Zip14 siRNA- vs. 
non-targeting siRNA-treated (Control siRNA) cells. Proteins with a fold change >1.136 or <0.88, and a false 
discovery rate <0.05, were included. Gene name, accession number, and ratio are listed, together with a short 
description (from uni-prot.org, using the descriptions from the human database, when not available for Rattus 
norvegicus). *Analyzed by the Blast function of uni-prot.org. RGD1560212 showed 88.6% homology with Mus 
musculus N-alpha acetyltransferase 11.
Figure 5. Western blotting of Chga (Chromogranin a) and B-actin (internal control). Sample 1–5 from left; 
Zip14 siRNA-treated samples. Sample 6–9 from left; non-targeted siRNA-treated samples (Control). 5 μg of 
protein were used.
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proteins was identified (ES = 1.7 and ES = 1.3, respectively). Of these, the majority were found to be mitochon-
drial (seven) and down-regulated (eight) (Table 4). Within the group of down-regulated proteins, an additional 
annotation cluster of mitochondrial proteins was identified (seven mitochondrial proteins, of which six were 
identified as mitochondrial transit proteins (ES = 1.6).
In summary, analysis of proteins that were differentially regulated following Zip14 silencing identified a group 
of mitochondrial proteins, especially ribosomal mitochondrial proteins, of which most were down-regulated.
Identification of mitochondrial proteins and pathways. In order to analyze the group of mitochon-
drial proteins further, we used the Mitocarda 2.0 compendium43 and found that 365 out of the 3431 quantified 
proteins can be assigned to the mitochondria. The general level of the mitochondrial proteins was not altered 
when comparing Zip14 siRNA- vs. non-targeting siRNA-treated (Control siRNA) cells (median ratio 0.98 of the 
365 proteins; Supplementary Material 6) indicating a similar level of mitochondrial proteins in the two groups.
When looking at the functions of the identified mitochondrial proteins, a total of 25 proteins of mitochondrial 
ribosomes were detected and all but 2 had ratio values (Zip14 siRNA vs non-targeted siRNA treatment) below 
1.0 (mean ratio of 0.89), supporting the findings of the gene ontology analysis (a total list of the 25 detected mito-
chondrial ribosomal proteins are found in Supplementary Material 7).
Of interest, proteins within the oxidative phosphorylation process seemed to be affected as well, with 33 
out of 34 proteins with a ratio value (Zip14 siRNA vs non-targeted siRNA treatment) below 1.0 (median 0.89) 
(Supplementary Material 8).
Proteins involved in the degradation of branched chain amino acids, fatty acid degradation, and citric acid 
cycle were not generally affected by Zip14 siRNA treatment, as the mean ratio of Zip14 siRNA vs. non-targeting 
siRNA treated (Control siRNA) cells were comparable (mean ratio of 0.99, 1.00, and 0.97, respectively).
Measurements of insulin secretion and storage in Zip14 siRNA-treated cells. Next, we investi-
gated the functional effects of Zip14 silencing on insulin secretion and storage after 24 h of glucose stimulation. 
The experiment was designed in a dose-related manner, in order to functionally investigate the insulin secre-
tion process, with glucose concentrations covering the response range originally found by Merglen et al. when 
Functional Annotation Clustering
Group 
cluster Gene name Accession Regulation Description
Ribosomal proteins (ES 1.7)*
Hnrnpr Q566E4 Down Heterogeneous nuclear ribonucleoprotein R
Mrpl11 A0A0G2JYU2 Down 39S ribosomal protein L11, mitochondrial
Mrpl28 D3ZJY1 Up 39S ribosomal protein L28, mitochondrial
Mrpl44 Q4G067 Down 39S ribosomal protein L44, mitochondrial
Mrps5 D3ZYT2 Down 28S ribosomal protein S5, mitochondrial
Mrps16 D4A7X1 Down 28S ribosomal protein S16, mitochondrial
Mrps30 D4A833 Down 28S ribosomal protein S30, mitochondrial
Mrps34 D4ABM5 Down 28S ribosomal protein S34, mitochondrial
Nop58 Q5PPK6 Down Nucleolar protein 58
Rpl22l1 B2RZD5 Up 60S ribosomal protein L22-like 1
Rps5 B0BN81 Up 40S ribosomal protein S5
Mitochondrial transit peptides (ES 1.6)**
Ccbl1 G3V827 Down Cysteine conjugate-beta lyase 1, isoform CRA_a
Cox7a2 B2RYS0 Down Cytochrome c oxidase subunit 7A2, mitochondrial
Dlst G3V6P2 Down Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate dehydrogenase complex, mitochondrial
Micu1*** A0A0G2K0T5 Down Calcium uptake protein 1, mitochondrial
Mrpl11 A0A0G2JYU2 Down 39S ribosomal protein L11, mitochondrial
Pdp2 A0A0G2JSL7 Down [Pyruvate dehydrogenase [acetyl-transferring]]-phosphatase 2, mitochondrial
Prdx3 G3V7I0 Down Thioredoxin-dependent peroxide reductase, mitochondrial
Table 4. Functional annotation clustering. Functional annotation clustering was performed using the 
bioinformatics software DAVID (https://david-d.ncifcrf.gov/). Proteins with ≥3 scans, ≥1 unique peptide, fold 
change >1.136 or <0.88, and a p-value < 0.05 were included and analyzed together, or separated into down-
regulated and up-regulated proteins. Two annotation clusters were found with an ES ≥1.3. *ES of 1.7 when 
interrogating the complete list of proteins. This cluster was also found when interrogating only down-regulated 
proteins (ES 1.3). **ES of 1.6 when investigating only down-regulated proteins. ***MICU1 is not classified as 
a transit peptide, but was within the cluster group as a mitochondrial protein. Gene names are listed, together 
with accession number and a short description of each gene and cluster. The description of genes was accessed 
from uni-prot.org, using the descriptions from the human database, when not available for Rattus norvegicus. 
ES: enrichment score.
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describing the INS-1E cell line35, The cells were thereby exposed to a range of hypo- to hyperglycemic conditions 
compared to their normal standard environment of 11 mM glucose.
Insulin secretion in the presence of 5, 16, or 24 mM glucose was not different between Zip14 siRNA- and 
control siRNA-treated INS-1E cells (p = 0.6991, p = 0.7922, and p = 0.6991, respectively) (Fig. 6A). Intracellular 
insulin content was, however, increased in Zip14 siRNA-treated cells, reaching statistical significance in cells 
incubated in 5, 16, and 24 mM glucose (p = 0.0152, p = 0.0043, and p = 0.0260, respectively) (Fig. 6B). Reflecting 
this, the ratio between secreted and intracellular insulin was decreased in the presence of 16 and 24 mM glucose 
in the Zip14 siRNA-treated cells (p = 0.0087 and p = 0.0260, respectively). At 5 mM glucose, the ratio showed the 
same pattern, although this effect was not statistically significant (p = 0.2403) (Fig. 6C). To investigate if Zip14 
in itself has an effect on the Insulin mRNA, the expression level of insulin (Ins) was measured at the basic condi-
tion of 11 mM glucose. Insulin (Ins) was found to be statistically comparable between Zip14 siRNA- and control 
siRNA-treated cells (p = 0.8182) (Fig. 6D).
Figure 6. Insulin secretion and intracellular insulin content of INS-1E cells treated with Zip14 siRNA or 
non-targeting siRNA at diverse glucose concentrations. Cells were treated with Zip14 siRNA or non-targeting 
siRNA (Control siRNA) and incubated for 24 h in medium containing 5 mM, 16 mM, or 24 mM glucose (n = 6 
replicates, except for 16 mM Control siRNA, where n = 5). Insulin measurements were performed using Rat 
Insulin Elisa kits and normalized to the protein concentration. Data are mean ± SEM. *p < 0.05, **p < 0.01. 
(A) Insulin secretion, expressed as µIU insulin/µg of protein. (B) Intracellular insulin content, expressed as 
µIU insulin/µg of protein. (C) Insulin secretion/intracellular insulin content ratio. (D) Insulin (Ins) mRNA 
expression at 11 mM glucose, expressed as mean starting quantity of (insulin/three house-keeping genes) ± SEM, 
measured by real-time PCR.
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In summary, increased intracellular insulin content, in combination with unaltered insulin (Ins) gene expres-
sion and secretion of insulin, was observed following Zip14 silencing.
Effect of Zip14 silencing on cell viability, apoptosis, and necrosis. To functionally investigate 
whether Zip14 influences cell survival, cell viability, apoptosis, and necrosis were quantified in Zip14 siRNA- and 
control siRNA-treated cells at diverse glucose concentrations, alongside measurement of the Bax/Bcl-2 mRNA 
expression index as an indicator of activation of the intrinsic apoptotic pathway.
The general viability of both Zip14 siRNA-treated and control siRNA-treated cells was high, with a mean 
viability between 84% and 89%. The percentage of viable cells, showed no difference when comparing Zip14 
siRNA treated cells vs. siRNA controls (5 mM glucose, p = 0.7572; 11 mM, p = 0.4797; 16 mM, p = 0.0932; 24 mM, 
p = 0.4013) (Fig. 7A).
Figure 7. Overall viability, apoptosis, necrosis, and Bax/Bcl-2 index in INS-1E cells treated with Zip14 siRNA or 
non-targeting siRNA after 24 h incubation in diverse glucose concentrations. INS-1E cells were transfected with 
Zip14 siRNA or non-targeting siRNA (Control siRNA) and incubated for 24 h in medium containing 5 mM, 11 mM, 
16 mM, or 24 mM glucose. Viability measurements were performed using Via1-cassettes (Chemometec, Denmark) in 
a Nucleocounter NC-3000 (experiment performed twice, n = 9 in total). A Cell Death Detection ELISAPLUS kit was 
used for the measurement of apoptosis or necrosis. Detection was performed using an ELISA Reader at 405 nm. n = 6 
in each group, except for the 16 mM Control siRNA group, where n = 4. Data are mean ± SEM. (A) Percentage of 
viable cells, assessed using acridine orange and DAPI staining. (B) Apoptosis, measured as the amount of intracellular 
histone-associated DNA fragments. (C) Necrosis, measured as the amount of histone-associated DNA fragments in 
the culture medium. *p < 0.05. (D) The Bax/Bcl-2 index, measured by real-time PCR. Gene expression was measured 
as mean starting quantity (gene of interest/three house-keeping genes) ± SEM.
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Despite comparable overall viability, active apoptosis, assessed by quantifying intracellular histone-associated 
DNA fragments, was decreased in Zip14 siRNA-treated INS-1E cells. This result was statistically significant at 
16 mM glucose and close to significance at 5 mM glucose (p = 0.0190 and p = 0.0649, respectively). The same 
tendency was found after incubation in 11 and 24 mM glucose, although these differences were not statistically 
significant (p = 0.2403 and p = 0.1797, respectively) (Fig. 7B).
Necrotic beta-cell death, judged by quantifying histone-associated DNA fragments in the culture superna-
tant, showed the same pattern as for apoptosis, with a decrease in Zip14 siRNA- vs. control siRNA-treated cells. 
The difference was significant at 11 mM (p = 0.0411), but not at 5, 16, or 24 mM (p = 0.6991, p = 0.7619, and 
p = 0.1320, respectively) (Fig. 7C).
In addition, the bax/bcl2 ratio, an indicator of susceptibility to apoptosis, was measured by real-time PCR at 
11 mM glucose. However, there was no effect of Zip14 silencing on this parameter (Fig. 7D).
In summary, signs of decreased apoptosis and necrosis were found in Zip14-silenced cells, but there was no 
effect on the general viability of the cells or the Bax/Bcl-2 index.
Discussion
Studies of Zip14 knockout mice suggest a role for Zip14 in glucose homeostasis and beta-cell function, because 
Zip14 knockout animals display high circulating insulin levels, alongside signs of an insulin secretory deficit 
during high glucose stimulation26,31. Further, the pancreatic expression level of Zip14 is low in type 2 diabetic 
individuals22. In this study, we confirmed the presence of Zip14 in INS-1E cells and showed effects of glucose 
concentration on its mRNA expression. Using targeted proteomics, we identified the Zip14 protein within the 
60–100 kDa range, which was comparable to findings of Liuzzi and co-authors, who reported a band size for 
Zip14 of 70 kDa by western blotting in AML12 hepatocytes. This apparent molecular mass is hypothesized to be 
due to glycosylation, given that Zip14 has a predicted size of 54 kDa, which is also observed in other cell-types56. 
The functional studies supported a role for Zip14 in insulin processing and also potentially in mitochondrial 
function, because the expression of a group of ribosomal mitochondrial proteins as well as the general level of 
mitochondrial proteins involved in oxidative phosphorylation was affected by Zip14 silencing in our large-scale 
proteomic analysis. We were able to perform the sub-analyses of mitochondrial proteins due to the high amount 
of mitochondrial proteins measured by large scale proteomics.
Mitochondrial function is essential for insulin secretion, because ATP is the main signal that initiates insulin 
secretion. Upon glucose stimulation, ATP is generated within the mitochondria through oxidative phosphoryl-
ation57. Mitochondrial DNA encodes proteins that are essential for oxidative phosphorylation, and the mRNAs 
corresponding to these proteins are translated by mitochondrial ribosomes, which are encoded by nuclear DNA58. 
Several of these proteins were found to be significantly down-regulated at the protein level in this study. The 
potential importance of these proteins is underlined by the fact that, in rho0 MIN6 and INS-E cells, which lack 
the mitochondrial genome, glucose-stimulated insulin secretion is absent59,60. Of interest, one of the main pro-
teins, Slirp, required for efficient translocation of mRNA to the mitochondrial ribosome, was found to be signifi-
cantly down-regulated in Zip14 siRNA treated samples vs. control (Ratio 0.86, listed in Table 2)61.
Examining the 34 mitochondrial proteins directly involved in oxidative phosphorylation, the mean ratio of 
Zip14 siRNA/non-targeted siRNA was found to be 0.89 indicating a general lower level of proteins involved in 
this process in a Zip14 deficient state. Relevant, the oxidative phosphorylation protein Cox7a2, was found to be 
significantly down-regulated (Table 4). Cox7a2 is an important assembly factor in the respiratory chain, modulat-
ing the interaction between complexes III (CIII) and IV (CIV) thereby optimizing cellular metabolism62.
Zinc ions regulate genes at a transcriptional level, through the transcription factor, metal-regulatory tran-
scription factor 1, and it may be that silencing of Zip14 thereby affects the production of other proteins with a 
mitochondrial function. The observed low expression levels of proteins involved in the mitochondrial protein 
translation are supported by our findings of a general lower level of mitochondrial oxidative phosphorylation 
proteins. The dysregulated insulin secretion, as seen in our functional insulin secretion studies, might be a con-
sequence of compromised mitochondrial metabolism. In the pathology of diabetes, mutations in mitochondrial 
DNA, as well as altered translation of these genes into proteins, are believed to play a role57,58. Around 1% of all 
cases of diabetes mellitus are thought to arise from mutations within mitochondrial DNA57.
In our functional studies of the insulin secretion process, a decreased ratio of secreted insulin to intracellu-
lar insulin content was observed upon a Zip14 down-regulation, further reflected in an increased intracellular 
insulin content at all measured glucose concentrations (Fig. 6.). Because insulin (Ins) expression was not affected 
by Zip14 silencing in cells cultured in 11 mM glucose, the accumulation of intracellular insulin likely reflect an 
abnormal secretion process induced by the partial deficiency of Zip14.
In line with the dysregulated insulin secretion observed in Zip14 siRNA treated cells, the expression of pro-
teins involved in insulin secretion was also affected by Zip14 silencing. Of special interest was the up-regulation 
of chromogranin A (Chga), which was further confirmed by western blotting. Chga is a well-known secretory 
granule protein that has several peptide derivatives, including betagranin and pancreastatin, which strongly 
inhibit glucose-stimulated insulin release54,55. In line with this, Chga knock-out mice exhibit an increased 
glucose-stimulated insulin secretion and recent research further suggest that Chga is linked to the regulation 
of mitochondrial volume, as knock-down of Chga in beta-cells results in increased mitochondrial volume and 
expression of mitochondrial proteins53.
In addition, 6-phosphofructo-2-kinase/fructose-2, 6-biphosphatase 2 (Pfkfb2) expression was 
down-regulated. Studies of INS-1E cells have shown a stimulatory effect of Pfkfb2 on insulin secretion, which 
was hypothesized to be linked to its glucokinase activity63. Further, the continuous and stable release of insulin 
in response to glucose is dependent on mitochondrial Ca2+ import by the Ca2+ uniporter (MCU)64. Interestingly, 
our studies showed a significant down-regulation of the mitochondrial calcium uptake protein 1 (Micu1), which 
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is a known subunit and regulator of the MCU transporter57. Furthermore, functional studies in HELA cells have 
shown that Micu1 is required for mitochondrial Ca2+ uptake by the Ca2+ uniporter65.
Despite the possibility that mitochondrial dysfunction might lead to increased levels of oxidative stress and 
subsequently cell death66, Zip14 silencing did not inhibit cell viability. Instead lowered apoptosis and necrosis 
were indicated by measurement of histone-associated DNA fragments in Zip14 silenced cells and the surround-
ing medium, respectively. However, no differences were detected in Bax/Bcl-2 expression, which are regulators of 
the intrinsic apoptotic pathway, dependent on mitochondrial cytochrome c release66. The extent to which Zip14 
expression influences apoptosis and necrosis remains unclear, because cell viability was high and unaffected by 
a 30% down-regulation of the Zip14 protein. Given that some degree of apoptosis inevitably occurs following 
rapid cell proliferation, our findings might reflect a decreased proliferative rate in the Zip14 siRNA-treated cells. 
Zip14 plays a general role in proliferation and differentiation, indicated by the decreased proliferation and differ-
entiation of chondrocytes, hepatocytes, and adipocytes in Zip14 knockout mice24,27,32. Consistent with this, the 
proliferation marker protein Ki-67 (Mki67) was significantly down-regulated following Zip14 siRNA treatment. 
Mki67 is a reliable marker of proliferation, because it is highly expressed in all phases of proliferation, but absent 
in the resting state67.
The observed functional effects of Zip14 silencing likely reflect changes in intracellular zinc homeostasis, 
because Zip14 functions as a zinc importing protein. The zinc transporter family consists of no less than 10 Znts 
and 14 Zips68. However, the complexity and interplay of these zinc transporters are far from understood. Znt1 
is known as a main and generally expressed zinc-exporting protein at the plasma-membrane, however no effect 
was found on Znt1 expression upon a Zip14 down-regulation indicating no compensatory effect by this general 
zinc-efflux transporter46. As Znt 3, 5, and 8 are localized at the insulin granules and thought to play an important 
functional role in regulating the glucose-stimulated insulin secretion, one could have suspected an effect of a 
Zip14 down-regulation as insulin secretion was affected in our experiment5,47–49. In this study, no such effect was 
found, indicating that their role is not directly dependent on Zip14 function. Regarding the Zip family, we choose 
to investigate Zip6 and Zip9, both hormone-sensitive transporters, that like Zip14 seems to have a function in 
apoptosis and proliferation in various cell types, however no indications of a regulatory interplay was found 
upon a Zip14 regulation50,51. Additionally, Zip13 was measured, as an interesting transporter in terms of Zip14, 
as Zip13 and Zip14 knock-out mice share many similarities i.e. impaired glucose homeostasis and growth retar-
dation and could therefore be a potential target for a compensatory mechanism52. Overall, the change in Zip14 
expression was not compensated for by any of the other zinc transporters measured (Znt 1, 3, 5, 8 and Zip 6, 9, 
13), pointing at a functional change in intracellular zinc homeostasis upon a Zip14 regulation. Albeit, it cannot 
be excluded that the down-regulation of Zip14 was compensated by other zinc transporters beyond the scope of 
our investigations.
A decreased amount of cytosolic zinc following a Zip14 down-regulation has been indicated by a reduced Mt1 
expression in a study by Troche and co-authors, investigating Zip14 siRNA-treated adipocytes24. In our experi-
ments, we detected an up-regulation of Mt1a expression following Zip14 silencing. This might reflect increased 
levels of oxidative stress resulting from mitochondrial dysfunction, with Mt1a being up-regulated to scavenge 
free radicals and thereby prevent cell death12.However, in support of a change in intracellular metals upon Zip14 
silencing, the expression of several metal-binding proteins was altered, including ACO1, which is an iron-sensing 
protein69. Notably, Zip14 plays an important role as an iron transporting protein in liver29,70, and it cannot be 
excluded that dysregulation of iron homeostasis contributes to the cellular phenotype that we have described.
The INS-1E cells are were cultivated at 11 mM glucose as originally described by Merglen et al. and Asfari 
et al.35.36. The glucose-stimulation experiments were designed in a dose-related manner, using diverse glucose 
concentrations ranging from low (5 mM) to high glucose (24 mM), in order to functionally investigate the 
glucose-stimulated response of the INS-1E cells focusing on the effect of a Zip14 siRNA down-regulation. One 
cannot exclude, that the cells were somehow glucose deprived at 5 mM, with the standard growth condition being 
11 mM. However, the viability of the cells at 5 mM were comparable with the other glucose concentrations (11,16 
or 24 mM), just as the pattern of apoptosis and necrosis were similar (Fig. 7) supporting that measurements of 
insulin secretion under such conditions are still feasible and reflect the regulatory function of glucose on INS-1E 
cells.
In conclusion, our results establish a role of Zip14 within the beta-cell and imply that a down-regulation of 
Zip14 impairs insulin processing and potentially affects mitochondrial function. As this is the first study into the 
function of Zip14 in the pancreatic beta-cell, future studies should aim at further exploring these novel links. 
Since signs of low pancreatic expression levels of Zip14 have been demonstrated in T2D, enhanced Zip14 activity 
could potentially serve as a future pharmacological target in the treatment of beta-cell dysfunction.
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